Candidate gene
|
Marker
| PCDH17 methylation may be a tumor-specific event and can be used as an epigenetic biomarker for nasopharyngeal carcinoma (NPC)  |
|
PCDH17 methylation in serum is a frequent event in Renal Cell Carcinoma and associated with risk factors of poor outcomes  |
|
PCDH17 methylation at diagnosis was closely related to poor prognosis and thus could be used as a new biomarker to predict relapse in patients with B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) |
|
detection of PCDH17 promoter methylation in serum-derived DNA may be a convenient and noninvasive predictive biomarker in routine clinical practice  |
Therapy target
|
|